ANEB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANEB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Anebulo Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2023 was $1.01 Mil. Anebulo Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $7.50 Mil. Therefore, Anebulo Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 was 0.14.
The historical data trend for Anebulo Pharmaceuticals's Liabilities-to-Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anebulo Pharmaceuticals Annual Data | |||||||||
Trend | Jun20 | Jun21 | Jun22 | Jun23 | |||||
Liabilities-to-Assets | 1.06 | 0.01 | 0.03 | 0.09 |
Anebulo Pharmaceuticals Quarterly Data | ||||||||||||||
Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Liabilities-to-Assets | Get a 7-Day Free Trial | 0.08 | 0.10 | 0.09 | 0.08 | 0.14 |
For the Biotechnology subindustry, Anebulo Pharmaceuticals's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Anebulo Pharmaceuticals's Liabilities-to-Assets distribution charts can be found below:
* The bar in red indicates where Anebulo Pharmaceuticals's Liabilities-to-Assets falls into.
Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.
Anebulo Pharmaceuticals's Liabilities-to-Assets Ratio for the fiscal year that ended in Jun. 2023 is calculated as:
Liabilities-to-Assets (A: Jun. 2023 ) | = | Total Liabilities | / | Total Assets |
= | 1.069 | / | 11.67 | |
= | 0.09 |
Anebulo Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2023 is calculated as
Liabilities-to-Assets (Q: Dec. 2023 ) | = | Total Liabilities | / | Total Assets |
= | 1.014 | / | 7.501 | |
= | 0.14 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anebulo Pharmaceuticals (NAS:ANEB) Liabilities-to-Assets Explanation
Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.
Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Bimal R. Shah | director | C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTER AVENUE, SUITE 240, HENDERSON NV 89052 |
Richard Anthony Cunningham, | director, officer: Chief Executive Officer | ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139 |
Dan George | officer: Chief Financial Officer | 1412 62ND STREET, EMERYVILLE CA 94608 |
Sandra A. Gardiner | officer: Acting Chief Financial Officer | CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005 |
Kenneth C Cundy | officer: Chief Scientific Officer | 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025 |
Nathaniel Calloway | director | C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734 |
Simon Allen | director, officer: Chief Executive Officer | C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037 |
Aron R. English | director, 10 percent owner | 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107 |
Kenneth Lin | director | PO BOX 1005, LOS ALTOS CA 94022 |
Karah Herdman Parschauer | director | 60 LEVERONI COURT, NOVATO CA 94949 |
22nw Fund, Lp | 10 percent owner | 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107 |
Joseph F. Lawler | director, 10 percent owner | 2110 RANCH ROAD 620 S, #341732, LAKEWAY TX 78734 |
Areta Kupchyk | director | C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734 |
Jason Aryeh | director | 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037 |
22nw, Lp | 10 percent owner, other: See Explanation of Response | 590 1ST AVE S, UNIT C1, SEATTLE WA 98104 |
From GuruFocus
By PRNewswire PRNewswire • 05-11-2023
By Business Wire Business Wire • 05-24-2022
By Business Wire Business Wire • 09-22-2021
By Business Wire Business Wire • 02-11-2022
By Business Wire Business Wire • 01-03-2022
By Business Wire Business Wire • 08-23-2022
By Business Wire • 10-06-2023
By Business Wire Business Wire • 06-23-2022
By Business Wire • 11-14-2023
By Business Wire • 10-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.